Analyzing Petros Pharmaceuticals (NASDAQ:PTPI) and MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$36.01 million	($1.29)	-33.96
Petros Pharmaceuticals	$5.82 million	0.52	-$8.16 million	($4.76)	-0.06

Petros Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for MoonLake Immunotherapeutics and Petros Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0	1	6	1	3.00
Petros Pharmaceuticals	0	0	0	0	0.00

MoonLake Immunotherapeutics presently has a consensus target price of $84.29, indicating a potential upside of 92.39%. Given MoonLake Immunotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than Petros Pharmaceuticals.

Risk & Volatility

MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Profitability

This table compares MoonLake Immunotherapeutics and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-15.54%	-15.09%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

MoonLake Immunotherapeutics beats Petros Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.